Skip to content
Home » AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 billion

AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 billion

    The deal values Icosavax at $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5 per share in cash if certain milestones are met. The upfront payment of $15 apiece represents a premium of about 43% to U.S.-listed Icosavax's last close.

    Read full NASCAR article on Yahoo Sports

    Read all NASCAR articles